Post-earnings recap
Reported
Mon, Aug 15, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that IDEAYA Biosciences I is facing challenges, particularly reflected in their EPS miss. The stock's significant drop of 34.82% suggests investor concerns about the company's financial health and future prospects. Without guidance, uncertainty remains about their upcoming performance and strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | -0.71% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs despite the current challenges.